China Universal Asset Management Company’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $2.5M | Sell |
19,877
-122
| -0.6% | -$15.3K | 0.24% | 87 |
|
|
2025
Q1 | $2.21M | Sell |
19,999
-1,469
| -7% | -$162K | 0.21% | 98 |
|
|
2024
Q4 | $2.93M | Buy |
21,468
+2,047
| +11% | +$279K | 0.27% | 76 |
|
|
2024
Q3 | $2.24M | Buy |
19,421
+7,597
| +64% | +$875K | 0.25% | 89 |
|
|
2024
Q2 | $1.63M | Sell |
11,824
-7,324
| -38% | -$1.01M | 0.23% | 81 |
|
|
2024
Q1 | $2.64M | Buy |
19,148
+7,784
| +68% | +$1.07M | 0.34% | 64 |
|
|
2023
Q4 | $1.5M | Buy |
11,364
+8,860
| +354% | +$1.17M | 0.29% | 82 |
|
|
2023
Q3 | $282K | Buy |
2,504
+1,225
| +96% | +$138K | 0.08% | 130 |
|
|
2023
Q2 | $121K | Sell |
1,279
-30
| -2% | -$2.83K | 0.04% | 147 |
|
|
2023
Q1 | $132K | Buy |
1,309
+332
| +34% | +$33.6K | 0.04% | 125 |
|
|
2022
Q4 | $117K | Buy |
977
+81
| +9% | +$9.68K | 0.05% | 117 |
|
|
2022
Q3 | $95K | Buy |
+896
| New | +$95K | 0.04% | 111 |
|